InvestorsHub Logo
Followers 63
Posts 3143
Boards Moderated 0
Alias Born 03/06/2014

Re: cwwan1 post# 121223

Sunday, 03/23/2014 2:09:50 PM

Sunday, March 23, 2014 2:09:50 PM

Post# of 158400
About FDA Orphan designations:

Please read the following from the FDA regarding FDA Orphan Designation, I also believe that HemaXellerate is considered a biological product in this repect:

http://www.fda.gov/forindustry/DevelopingProductsforrareDiseasesConditions/default.htm

http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/HowtoapplyforOrphanProductDesignation/default.htm

http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/SmallBusinessAssistance/UCM311928.pdf

Also important are the grants and tax benefits for Orphan drugs:

The OOPD administers two extramural grant programs. The Orphan Products Grants Program provides funding for clinical research that tests the safety and efficacy of drugs, biologics, medical devices and medical foods in rare diseases or conditions. The Pediatric Device Consortia (PDC) Grant Program provides funding to develop nonprofit consortia to facilitate pediatric medical device development.

What you get from FDA Orpan Approval:

- Seven-year marketing exclusivity to the first sponsor obtaining FDA approval of a
designated drug
- Tax credit equal to 50% of clinical investigation expenses
- Exemption/Waiver of PDUFA application (filing) fees
- Assistance in the drug development process
- Orphan Products Grant funding
Soruce: http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/SmallBusinessAssistance/UCM311928.pdf

If HemaXellerate is approved as a FDA Orphan treatment/drug, we should be able to receive a grant for the clinical trails of HemaXellerate.

In the PROSPECTUS, Regen BioPharma believes that HemaXellerate qualifies as shown below:

The Company believes that this application of HemaXellerate qualifies for Orphan designation under the Orphan Drug Act due to the fact that aplastic anemia is a rare disease with prevalence in the United States of less than 200,000 and intends to apply to the FDA for Orphan designation for HemaXellerate.

http://www.sec.gov/Archives/edgar/data/1589150/000155479514000018/regforms1a11014.htm

The opinions, comments, or concerns, expressed herein, are solely that of the screen name 'd5wr59mfi8'. They are not to be misconstrued as legal or financial advice and should not be followed. For financial advice, please see the guidance of financial p

Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.